Русский / English
Enter the query
Petrovax Pharm
the company makes significant investments in a broad range of research and development efforts
13.3 mln doses
of flu vaccine supplied to Russia’s regions
In accordance with the National Immunization Calendar, NPO Petrovax Pharm supplies 13.3 mln doses of Grippol® Plus vaccine. The primary vaccine recipients are the regions in the Far East Federal District that had experienced flooding: Khabarovsk Kray and the Amur and Jewish autonomous regions.

Working with Pfizer, NPO Petrovax Pharm implements a fully integrated production cycle to manufacture, monitor, and ensure quality control of the 13-valent pneumococcal conjugate vaccine, and produces the first few commercial batches. 

Over the course of the year, the company organizes a number of philanthropic initiatives. Together with Pfizer, it supports the Rostropovich-Vishnevskaya Foundation’s For the Health & Future of Children Program. Petrovax Pharm sends assistance to the flooded regions in the Far East Federal District and organizes a blood drive in conjunction with the Hematology Research Center’s Free Blood Donation Program.

The company begins work on a new development strategy. At the end of the year, Interros Holding enters into an agreement with NPO Petrovax Pharm to acquire a controlling stake in the company.
16.9 mln doses
will be shipped to regionals with framework of the National Immunisation Schedule
The company of Vladimir Potanin, founder of the Interros Group, finalizes the acquisition of the controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.
>20 mln doses
vaccines against flue and pneumococcus Petrovax will produce in 2015
Will be shipped to regionals with framework of National Immunisation Schedule.
Localized production of the Grippol® Plus flu vaccine in Belarus

February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.

Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.

June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-of-the-art medicines for cardiovascular diseases.

July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.

August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.

October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.

Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.

Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.

11 countries
import products manufactured by the company
In 2018 year
a new Grippol® Quadrivalent vaccine will be launched